• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于在网络荟萃分析中联合组合无进展生存期和总生存期证据的非参数方法。

A non-parametric approach for jointly combining evidence on progression free and overall survival time in network meta-analysis.

机构信息

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Value, Access & Devolved Nations, Merck Sharp and Dohme (UK) Ltd, London, UK.

出版信息

Res Synth Methods. 2022 Sep;13(5):573-584. doi: 10.1002/jrsm.1539. Epub 2022 Jan 10.

DOI:10.1002/jrsm.1539
PMID:34898019
Abstract

Randomised controlled trials of cancer treatments typically report progression free survival (PFS) and overall survival (OS) outcomes. Existing methods to synthesise evidence on PFS and OS either rely on the proportional hazards assumption or make parametric assumptions which may not capture the diverse survival curve shapes across studies and treatments. Furthermore, PFS and OS are not independent; OS is the sum of PFS and post-progression survival (PPS). Our aim was to develop a non-parametric approach for jointly synthesising evidence from published Kaplan-Meier survival curves of PFS and OS without assuming proportional hazards. Restricted mean survival times (RMST) are estimated by the area under the survival curves (AUCs) up to a restricted follow-up time. The correlation between AUCs due to the constraint that OS > PFS is estimated using bootstrap re-sampling. Network meta-analysis models are given for RMST for PFS and PPS and ensure that OS = PFS + PPS. Both additive and multiplicative network meta-analysis models are presented to obtain relative treatment effects as either differences or ratios of RMST. The methods are illustrated with a network meta-analysis of treatments for stage IIIA-N2 non-small cell lung cancer. The approach has implications for health economic models of cancer treatments, which require estimates of the mean time spent in the PFS and PPS health-states. The methods can be applied to a single time-to-event outcome, and so have wide applicability in any field where time-to-event outcomes are reported, the proportional hazards assumption is in doubt, and survival curve shapes differ across studies and interventions.

摘要

癌症治疗的随机对照试验通常报告无进展生存期 (PFS) 和总生存期 (OS) 结果。现有的综合 PFS 和 OS 证据的方法要么依赖于比例风险假设,要么进行参数假设,这些假设可能无法捕捉到不同研究和治疗中的各种生存曲线形状。此外,PFS 和 OS 并不独立;OS 是 PFS 和进展后生存 (PPS) 的总和。我们的目的是开发一种非参数方法,用于综合发表的 PFS 和 OS 的 Kaplan-Meier 生存曲线的证据,而无需假设比例风险。受限平均生存时间 (RMST) 通过生存曲线下的面积 (AUC) 来估计,直至受限随访时间。由于 OS > PFS 的约束,AUC 之间的相关性使用 bootstrap 重采样进行估计。为 PFS 和 PPS 提供了 RMST 的网络荟萃分析模型,并确保 OS = PFS + PPS。同时呈现了加法和乘法网络荟萃分析模型,以获得作为 RMST 差异或比值的相对治疗效果。该方法通过对 IIIA-N2 期非小细胞肺癌治疗的网络荟萃分析进行了说明。该方法对癌症治疗的健康经济模型有影响,需要估计 PFS 和 PPS 健康状态下花费的平均时间。该方法可应用于单个时间到事件结果,因此在报告时间到事件结果、比例风险假设存在疑问以及生存曲线形状因研究和干预而异的任何领域都具有广泛的适用性。

相似文献

1
A non-parametric approach for jointly combining evidence on progression free and overall survival time in network meta-analysis.一种用于在网络荟萃分析中联合组合无进展生存期和总生存期证据的非参数方法。
Res Synth Methods. 2022 Sep;13(5):573-584. doi: 10.1002/jrsm.1539. Epub 2022 Jan 10.
2
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.治疗胶质母细胞瘤进展或复发的选择:网络荟萃分析。
Cochrane Database Syst Rev. 2021 May 4;5(1):CD013579. doi: 10.1002/14651858.CD013579.pub2.
3
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
4
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.未治疗的霍奇金淋巴瘤患者化疗和放疗在第二原发性恶性肿瘤、总生存期和无进展生存期方面的优化:个体参与者数据分析
Cochrane Database Syst Rev. 2017 Sep 13;9(9):CD008814. doi: 10.1002/14651858.CD008814.pub2.
5
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.伊立替康、奥沙利铂和雷替曲塞用于治疗晚期结直肠癌:系统评价与经济学评估
Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. doi: 10.3310/hta12150.
6
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).纳武单抗用于成人霍奇金淋巴瘤(使用RobotReviewer软件进行的快速综述)
Cochrane Database Syst Rev. 2018 Jul 12;7(7):CD012556. doi: 10.1002/14651858.CD012556.pub2.
7
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.仑伐替尼联合帕博利珠单抗治疗未经治疗的晚期肾细胞癌:系统评价和成本效果分析。
Health Technol Assess. 2024 Aug;28(49):1-190. doi: 10.3310/TRRM4238.
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
9
Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.老年新诊断胶质母细胞瘤的治疗:一项网状Meta分析
Cochrane Database Syst Rev. 2020 Mar 23;3(3):CD013261. doi: 10.1002/14651858.CD013261.pub2.
10
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.

引用本文的文献

1
Informing Structural Assumptions for Three State Oncology Cost-Effectiveness Models through Model Efficiency and Fit.通过模型效率和拟合度为三个州立肿瘤学成本效益模型提供结构假设。
Appl Health Econ Health Policy. 2024 Sep;22(5):619-628. doi: 10.1007/s40258-024-00884-2. Epub 2024 May 21.
2
What is the optimal management of potentially resectable stage III-N2 NSCLC? Results of a fixed-effects network meta-analysis and economic modelling.可切除的Ⅲ-N2期非小细胞肺癌的最佳管理方案是什么?固定效应网络荟萃分析和经济模型的结果。
ERJ Open Res. 2023 Apr 3;9(2). doi: 10.1183/23120541.00299-2022. eCollection 2023 Mar.